Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AOC2 | O75106 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11555149 | 0.83 | ELANE (0.45) | LMNAKDM4ENPSR1TSHRKMT2A | |
| SCHEMBL22833645 | 0.83 | SMN1; SMN2 (0.37) | LMNASMN1; SMN2KDM4EBRD4TDP1 | |
| SCHEMBL11105046 | 0.80 | KMT2A (0.38) | SMN1; SMN2KDM4EAOC2TSHRKMT2A | |
| SCHEMBL3713600 | 0.79 | MEN1 (0.43) | LMNAKDM4EAOC2TSHRKMT2A | |
| SCHEMBL3788590 | 0.77 | CHRM5 (0.41) | LMNASMN1; SMN2KDM4ETDP1KMT2A | |
| SCHEMBL22833539 | 0.76 | AOC2 (0.39) | LMNASMN1; SMN2KDM4EAOC2BRD4 | |
| SCHEMBL15889048 | 0.74 | POLB (0.39) | LMNASMN1; SMN2KDM4ETDP1TSHR | |
| SCHEMBL23754685 | 0.74 | AOC2 (0.35) | KDM4EAOC2TSHRMAOB | |
| SCHEMBL13075652 | 0.73 | ATM (0.40) | LMNASMN1; SMN2KDM4ETDP1NPSR1 | |
| SCHEMBL13075305 | 0.73 | HTT (0.44) | LMNASMN1; SMN2NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | LMNA 1857/4885SMN1; SMN2 2246/4885KDM4E 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.